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comparable with respect to disease risk, cytogenetics, graft
composition, and post HCT complications (>Gr 2 acute
graft versus host disease (GVHD), CMV viremia), except for
engraftment syndrome which was more frequent in the
non-relapse group. Relapsed cohort had a higher incidence
(63% vs 31%) of partial T-cell chimerism, speciﬁcally lower
T-cell chimerism at engraftment and D30 (75%, 74.5%)
compared to non relapsers (90.5% and 94%), but was not
statistically signiﬁcant (p¼0.5 and p¼0.3).
Conclusions: Relapse is a major cause of mortality in pa-
tients that undergo HCT for AML/MDS. Relapse frequently
occurred early post HCT, in patients receiving RIC regimens
or those with partial donor T-cell chimerism at engraftment
and D30 post HCT in this small cohort. Further analyses are
ongoing to identify a subgroup of patients in whom pre-
emptive intervention is warranted.278
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Background: Graft failure following unrelated cord blood
transplantation (UCBT) in patients with Fanconi anemia is
associated with signiﬁcant mortality. Second transplantation
may be considered; however, the limited toxicity proﬁle of
hematopoietic growth factors makes them an option for the
treatment of graft failure. We describe a 7-year-old female
with Fanconi anemia and marrow failure treated with UCBT
utilizing a 6/6 HLA matched cord blood unit. The course was
complicated by secondary graft failure treated with he-
matopoietic growth factors including granulocyte colony
stimulating factor (GCSF), erythropoietin (EPO), and romi-
plostim with reversal of pancytopenia and transfusion
dependence. The use of hematopoietic growth factors in the
treatment of secondary graft failure following UCBT in pe-
diatric patients with Fanconi anemia might be considered as
alternative to re-transplantation.
Methods: The preparative regimen included total body
irradiation (3 Gy), ﬂudarabine (35 mg/m2/day x 4 days),
cyclophosphamide (10 mg/kg/day x 4 days), and thymoglo-
bulin (3 mg/kg/day x 4 days). Graft-versus-host disease
(GVHD) prophylaxis included cyclosporine and mycophe-
nolate mofetil. A total of 11.6 x 10
ˇ
7 TNC/kg and 0.9 x 10
ˇ
6
CD34/kg cell were infused. Engraftment occurred on Day +18.
No evidence of GVHD was noted and immunosuppression
was discontinued on Day +110. Post-HSCT complications
included: mucositis, respiratory syncitial virus infection,
adenovirus viremia, hemorrhagic cystitis, and cytomegalo-
virus (CMV) reactivation. On Day +79 CMV reactivation
reoccurred and valganciclovir was started on Day +87. On
Day +103 leukopeniawas noted and Bactrimwas stopped. On
Day +110, CMV was undetectable and valganciclovir was
stopped due to evolving cytopenias.
Results: Transfusionwith packed red blood cell and platelets
were provided. A bone marrow examination demonstrated a
hypocellular marrow (< 5%) and a normal cytogenetic
evaluation. On Day +188, engraftment analysis using whole
blood still demonstrated 98% donor DNA suggesting that the
few remaining stem cells were of donor origin. In order
to avoid the toxicity associated with second transplant, GCSF
(5 mcg/kg/day), romiplostim (10 mcg/kg/week), and EPO(150 units/kg/dose three times per week), was started on Day
+114, +117, and Day +119; respectively. By Day +130 the
absolute neutrophil count was > 500/uL and platelet count
was > 25,000/uL. By Day +149, the cytopenias and need for
transfusion support had resolved off of hematopoietic
growth factors.
Conclusion: To our knowledge, this is the ﬁrst description of
a successful application of hematopoietic growth factors as
initial therapy in a patient with secondary graft failure
following UCBT for Fanconi anemia. We found that the use of
hematopoietic growth factors to be an alternative to the
morbidity and mortality associated with the use of second
transplantation.279
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Despite signiﬁcant improvement in outcomes for patients
with pediatric non-Hodgkin lymphomas (NHL), relapsed
disease is associated with poor long-term survival. He-
matopoietic stem cell transplant (HSCT) is used to improve
outcome in this setting but there are limited data in pediatric
patients with NHL.
Methods: We now report on 29 pediatric patients who un-
derwent allogeneic HSCT at our institute between 1999-
2013.
Results: There were 16 male and 13 female patients and the
median age was 14 years (range 5-23 years). Histological
categories were anaplastic large cell lymphoma (ALCL)
(n¼9), lymphoblastic lymphoma (LL) (n¼8), diffuse large B
cell lymphoma (DLBCL) (n¼7), other B cell lymphomas
(Burkitt’s lymphoma¼1, Small cell, non-Burkitt’s high grade
lymphoma¼1, and T-cell rich, B-cell lymphoma¼1), and
other T-cell lymphoma (Stem cell myeloproliferative/T-cell
lymphoma¼1, and hepatosplenic T-cell lymphoma¼1). 9
patients received grafts from matched-related donors, 8
from matched-unrelated donors, 8 from mismatched-unre-
lated donors and 4 from haploidentical donors. 21/29
received a myeloablative conditioning regimen (MAC) while
8/29 patients received a reduced intensity conditioning
regimen (RIC). At the time of transplant, 23/28 patients were
in complete remission (CR¼10) or partial remission (PR¼13),
while 5/28 patients had persistent or progressive disease
based on standard established criteria. The 3eyear relapse
free survival (RFS) was 59% (95%CI: 37%-75%). The overall
outcomes varied based on the subtype of lymphoma: pa-
tients with ALCL had the best outcomes (9/9 patients are
alive and disease free) while those with LL had the worst (1
/8 patients is alive and disease free). Relapsed/progressive
disease was the cause of death for all 7 of the LL patients who
died. Patients with other B-cell and T-cell lymphomas also
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S212fared well (4/7 with DLBCL and 2/3 other B-cell lymphomas
and 2/2 other T-cell lymphomas are alive and disease free).
Patients in CR or PR had a better OS (18/23) compared with
those patients with persistent or progressive disease at time
of transplant (0/5). 11/29 patients died (9 from relapse and 2
from treatment related mortality).
Conclusions: HSCT offers the possibility of cure for patients
with NHL, especially for patients with ALCL and for those
patients that have a good response to re-induction therapy
prior to transplant. Relapsed disease post-transplant remains
a major challenge for patients with LL and for patients
transplanted with non-responsive disease. Post transplant
therapies to target residual disease should be evaluated in
these patients.280
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Introduction: Infections with NTM species are reported in
immunocompromised patients (pts) post-HCT with little
information on associated risk factors. In HIV+ pts, routine
prophylaxis is indicated for those with CD4 counts of 100-
200cells/uL. We hypothesize CD4 counts 200 as a possible
risk factor for development of NTM infection in the pediatric
alloHCT setting. We report our center’s experience with NTM
infections to help identify risk factors, clinical signiﬁcance
and need for prophylactic therapy.
Methods: Pts 21 years undergoing HCT from 2001 to 2014
were included. Deﬁnition of NTM infection: Positive culture
for NTM species in blood, cerebrospinal ﬂuid (CSF), lungs, BM
or tissue. Only pts withMycobacterium Avium Complex (MAC)
infection were included. Controls (n¼19) were identiﬁed by
matching age, gender, and underlying disease. Descriptive
statistics was calculated and comparison between 2 groups
was carried with t-test for continuous variables and Fisher
exact test for categorical variables.
Results: Of 272 pts undergoing HCT, NTM was diagnosed in
11 pts with 17 HCT (autologous¼1; allogeneic¼16) per-
formed among these pts. Indications for HCT: malignant¼6
(55%), non-malignant¼5 (45%). Donor sources: sibling BM
(n¼3), sibling PB (n¼2), unrelated PB (n¼3) unrelated BM
(n¼3), or unrelated UCB (n¼5). Conditioning regimens:
myeloablative (n¼7), non-myeloablative (n¼6), no condi-
tioning (n¼3). Pts had MAC isolated from the following sites:
lungs (n¼5), CSF (n¼1), BM (n¼2), lymph node (n¼1), and
blood (n¼3). Median date from HCT to NTM diagnosis was
233 days (range: 15 to 724 days). Mean absolute CD4 count at
diagnosis was 137 +/- 143 cells/uL (1 unreported). All pts
began therapy with azithromycin, ethambutol, and rifabutin/
rifampin. Additive therapy included levoﬂoxacin (n¼3),
imipenem (n¼1), amikacin (n¼3), and gatiﬂoxacin (n¼1).
Treatment duration ranged from 53-459 days. Eight of 11 pts
had graft-vs-host disease (GVHD) with 75% (n¼6) diagnosedprior to the onset of NTM. Overall survival was 73%(n¼8).
Causes of death were: complications due to NTM, progres-
sive underlying disease, and pulmonary failure secondary to
chronic GVHD. Of the 8 surviving pts, 1 had recurrence, 5
cleared the infection, and 2 are in treatment.
No statistically signiﬁcant risk factors for NTM were
found, including presence of GVHD, CD4 count at diagnosis,
CMV viremia, or donor source. Similar results were obtained
when not controlling for these variables. No statistically
signiﬁcant difference was found between pts who developed
MAC infections and those that did not.
Discussion: These results were unable to identify low CD4
counts as a potential risk factor for NTM necessitating the
need for multicenter collaborations. NTM appears to be a
treatable disease, with the role of prophylaxis unclear. With
the extensive treatment duration, healthcare utilization costs
should also be evaluated.281
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Hematopoietic Stem Cell Transplantation (HSCT) plays an
important role in the treatment of children with Acute
Myeloid Leukemia (AML). Match related donor (MRD) and
Unrelated Cord Blood Transplantation (UCBT) for patients
who lack a sibling donor are the options of HSCT in our unit.
UCB offers the advantage of faster availability of banked
cryopreserved UCB units compared with unrelated bone
marrow grafts with similar results in survival. We report our
results of HSCT for AML. We analyzed 28 children receiving
allogeneic HSCT for AML, 17 UCBT and 11 HSCT from a MRD.
Cord blood units were selected with 1 or 2 HLA mismatch;
reduce intensity conditioning (RIC) in all except two UCBT
consists of ﬂudaradine andmelphalan. Conditioning for MRD
HSCT consists of BU16/Cy120. Graft vs host disease prophy-
laxis with cyclosporine/MTX for MRD HSCT and cyclo-
sporine/MMF o cyclosporine/methylprednisolone for UCBT.
Average for neutrophil recovery in UCBT and MRD HSCT was
21 and 19 days respectively, average for platelet recovery in
UCBT and MRD HSCT was 34 and 23 days respectively.
Transplant related mortality in UCBT and MRD HSCT 18% and
17% respectively, causes of death were relapse(5¼29%) grade
IV hepatic graft versus host disease(2) and bacterial sepsis(1)
for UCBT, causes of death in MRD HSCT were relapse (1¼9%)
cerebral infarction(1) and chronic graft versus host dis-
ease(1). With a median follow up of 1 year, overall survival
for entire cohort was 60.7%, overall survival for UCBT was
52.9% and 72.7% for MRD HSCT (p¼0.25). Despite being few
patients these results show no signiﬁcant difference in
overall survival between related donors and unrelated cord
blood. RIC with ﬂudarabine and melphalan is a promising
alternative in children; it shows an acceptable relapse rate
compared with other more toxic conditionings.282
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